Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects by Vossen, A.C.Th.M. (Ann) et al.
1492 A. C. T. M. Vossen et al. Eur. J. Immunol. 1995.25: 1492-1496 
Ann C. T. M. Vossen', 
G. John M. Tibbe', 
Martin J. Kroos', 
Jan G. J. van de Winke13, 
Robbed Benner' and 
Huub F. J. Savelkoull 
Department of Immunology, 
Erasmus University, Rotterdam, 
The Netherlands 
Department of Chemical 
Pathology, Erasmus University, 
Rotterdam, The Netherlands 
Department of Immunology, 
University Hospital, Utrecht, The 
Netherlands 
Fc receptor binding of anti-CD3 monoclonal 
antibodies is not essential for immunosuppression, 
but triggers cytokine-related side effects 
A major drawback to the use of OKT3, a mouse anti-CD3 monoclonal antibody 
(mAb), as an immunosuppressive agent is the associated cytokine release syn- 
drome. We used a mouse model to elucidate the properties of anti-CD3 mAb 
responsible for these cytokine-related side effects. We have previously demon- 
strated that the hamster anti-CD3 mAb 145-2C11 induced strong cytokine 
release and morbidity in vivo, whereas two rat anti-CD3 mAb 17A2 and KT3 did 
not. In the current study, we show that the mitogenic capacity of soluble anti- 
CD3 mAb in vitro correlates with their induction of side effects in vivo. Mitoge- 
nesis in vitro and tumor necrosis factor-a (TNF-a) release in vivo induced by 
anti-CD3 mAb could be inhibited by the anti-FcyR mAb 2.4G2, indicating that 
FcyR binding of anti-CD3 mAb is responsible for their mitogenic properties and 
for their induction of side effects. Importantly, the two non-mitogenic rat anti- 
CD3 mAb were equally capable of suppressing skin allograft rejection as the 
mitogenic hamster anti-CD3 mAb, suggesting FcyR binding of anti-CD3 mAb is 
not essential for their immunosuppressive properties. This suggestion is rein- 
forced by our demonstration that administration of 2.462 in vivo did not inter- 
fere with immunosuppression of skin allograft rejection by 145-2C11. These find- 
ings suggest that clinical use of non-mitogenic anti-CD3 mAb will result in effec- 
tive immunosuppression without cytokine-related side effects. 
1 Introduction 
The murine anti-CD3 mAb OKT3 is widely used for pre- 
vention and treatment of clinical organ allograft rejection 
because of its known immunosuppressive properties [l ,  21. 
However, treatment with this mAb is accompanied by 
severe clinical symptoms, such as fever, chills, nausea, 
vomiting, headache, and diarrhea. These side effects have 
been related to an early systemic release of several cyto- 
kines, such as IL-2, TNF-a, IFN-y and IL-6 [3, 41, proba- 
bly produced by activated T lymphocytes [5]. This so-called 
cytokine release syndrome precludes the use of anti-CD3 
mAb in the treatment of autoimmune diseases. 
We developed a mouse model to elucidate the properties of 
anti-CD3 mAb responsible for these undesirable side 
effects. The strength of this model is that it is based on three 
anti-CD3 mAb with similar immunosuppressive capacity in 
a mouse skin transplantation model [6]. Furthermore, all 
three mAb induced T cell depletion and TcWCD3 complex 
modulation [6]. One of these mAb, the hamster mAb 145- 
2Cl l  [7], triggers strong cytokine release, accompanied by 
severe physical reactions consisting of piloerection, hypo- 
thermia, hypomotility and diarrhea [8,9]. Interestingly, this 
was not observed with the anti-CD3 mAb 17A2 (rat IgG2b) 
[lo] and KT3 (rat IgG2a) [6, 111. 
In the present study, the role of FcyR was assessed by using 
an FcyR-blocking mAb, 2.462 [12] both in vitro and in 
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vivo. Our results demonstrate that FcyR binding in vivo is 
responsible for cytokine release and side effects following 
anti-CD3 mAb treatment. Most importantly, this study 
provides direct evidence that FcyR binding of anti-CD3 
mAb in vivo is not necessary for immunosuppression. 
Therefore, these data may have important clinical implica- 
tions. 
2 Materials and methods 
2.1 Monoclonal antibodies 
We used the anti-mouse CD3 mAb 17A2, rat IgG2b [lo], 
KT3, rat IgG2a [ l l ]  and 145-2C11, a hamster mAb [7]. 
2.462 [12], a rat IgG2b mAb directed against mouse 
FcyRIIIIII [ 131, that also binds FcyRI via its Fc-portion 
[12], and F(ab'), fragments of 2.462 (kindly provided by 
Dr. M. Daeron, Institut Curie, Paris, France [14]) were 
used to block FcyR binding of anti-CD3 mAb. As isotype 
control mAb, we used PH2-4a (rat IgG2b), PH2-104 (rat 
IgG2a), both directed against Escherichia coli p- 
galactosidase (kindly provided by Dr. J. van Denderen, 
Department of Immunology, Rotterdam, The Nether- 
lands), and anti-TcRy6 mAb GL3 (hamster Ig) [15]. We 
used P1.17, a mouse IgG2a Ab of unknown specificity [16], 
to compete for FcyRI binding. 
mAb were purified from hybridoma culture supernatants 
by protein 6 (Pierce, Oud-Beijerland, The Netherlands) 
affinity chromatography, as described [17]. 
2.2 Mice 
For all experiments in vitro and as skin graft recipients, we 
used C57BLKa mice (H-2b). B6.C-H-2b"1z (H-2bm12) mice 
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were used as skin graft donors. All mice were bred at the 
Department of Immunology of the Erasmus University, 
Rotterdam. Mice were kept in light-cycled rooms and had 
access to acidified water and pelleted food ad libitum. 
2.3 Proliferation assays 
Spleen cells (2 x 105/well) were cultured in 200 pl RPMI 
1640 medium (Gibco, Paisley, GB) supplemented with 
10% heat-inactivated FCS, 4 mM L-glutamine, 5 X M 
fi-mercaptoethanol, 100 IU/ml penicillin and 50 pg/ml 
streptomycin. Cells were incubated with different con- 
centrations of antLCD3 mAb in round-bottom tissue cul- 
ture plates (Falcon). Alternatively, cells were cultured on 
antLCD3 mAb coated flat-bottom tissue culture plates 
(Falcon). After 48 h of culture at 37 "C in 5 % C 0 2  in air, 
0.5 pCi [3H]thymidine was added to each well, and 18 h 
later, cells were harvested and [3H]thymidine incorpora- 
tion was measured in a liquid scintillation counter. The role 
of FcyR in antLCD3 induced mitogenesis was examined by 
adding 10 pg/ml 2.462 mAb or an equivalent molar 
amount (6.7 pg/ml) 2.4G2 F(ab')z fragments to culture 
wells. In other wells, 10 pg/ml P1.17 (mouse IgG2a) [16] 
was added to compete for high-affinity FcyRI binding. In 
control wells, cells were cultured with isotype-control mAb 
or Con A (5 pg/ml). 
2.4 Blocking of FcyR in vivo 
The role of FcyR binding in TNF-a release and immuno- 
suppression induced by 145-2C11 was examined by block- 
ade of FcyR in vivo. C57BL/Ka mice were injected i.p. 
with 250 pg of 2.462 mAb 12 to 18 h before injection of 
10 pg 145-2C11. Our primary goal was to achieve short- 
term blocking of FcyR, since the effects of 10 pg of 145- 
2Cll can be detected early after injection [6, 181. This dose 
of 2.462 has previously been shown to inhibit FcyR- 
mediated sequestration of immune complexes for at least 
24 h [19]. 
2.5 Detection of serum TNF-a 
For induction of TNF-a release, 10 pg 145-2C11 mAb were 
injected i.v. The role of FcyR in TNF-a release was studied 
by 2.4G2 administration, 12 to 18 h before 145-2C11 mAb 
injection. Control mice were injected with 2.462 alone or 
0.5 ml BSS. At 1, 2, 4, 8, and 24 h after 145-2C11 mAb 
injection, 3 or 5 mice per group were killed using carbon 
dioxide asphyxiation. Blood was obtained via heart punc- 
ture in sterile tubes and left to clot overnight at 4 "C. After 
centrifugation, serum samples were aliquotted and stored 
at - 70 "C. 
Serum TNF-a levels were determined by a cytotoxicity 
assay on WEHI-164 clone 13 cells [20]. Briefly, trypsinized 
WEHI-164 cells were seeded in flat-bottom tissue culture 
plates (Falcon) at 1 x lo4 cells/100 p1 complete medium. 
After overnight cell adherence at 37 "C, serum samples 
and actinomycin D (1 pg/ml) were added and incubated 
for 24 h at 37 "C. Cytotoxic activity was measured with the 
MTT assay [21]. 
2.6 Skin grafting 
The immunosuppressive effect of 145-2C11 mAb on MHC 
class 11-disparate skin allograft rejection was studied by 
administration of 10 pg mAb the day before grafting. 
FcyR-blockade was achieved by 2.462 mAb injection 12 to 
18 h before 145-2C11 treatment. Control mice received 
2.462 mAb alone or 0.5 ml BSS. 
Tail skin of B6.C-H-2bm" donors was grafted to the dorsal 
thorax of C57BWKa recipients using a modification of the 
method of Billingham and Medawar [22]. Grafts were con- 
sidered rejected when no viable donor skin was detectable. 
2.7 Statistical analyses 
The induction of T cell proliferation and TNF-a release by 
anti-CD3 mAb was compared by analysis of variance 
(ANOVA). If ANOVA revealed significant differences, 
the groups were compared using Student's t-test. Graft sur- 
vival of groups was compared by Mann Whitney tests. Val- 
ues of p < 0.05 were considered significant. 
3 Results 
3.1 T lymphocyte proliferation induced by immobilized 
and soluble anti-CD3 mAb 
To induce Tcell proliferation, antLCD3 mAb had to be 
cross-linked either by FcyR+ cells or by solid phase immo- 
bilized mAb. The use of immobilized antLCD3 mAb 
enabled the study of their mitogenic properties indepen- 
dent of their FcyR binding capacity [23]. Figure 1 A shows 
that immobilized anti-CD3 mAb, rat IgG2a and hamster 
mAb induced comparable T cell proliferation. The prolifer- 
ation curve of rat IgG2b anti-CD3 mAb was significantly 
different from that of the two other anti-CD3 mAb. At 
higher concentrations, 17A2 (rat IgG2b) was significantly 
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Figure 1. Proliferation induced by anti-CD3 mAb. C57BWKa 
spleen cells were stimulated with different concentrations of 
immobilized (A) or soluble (B) rat IgG2b, rat IgG2a or hamster 
anti-CD3 mAb. The data represent mean cpm of triplicate cul- 
tures f SD. Experiments were repeated three times, yielding 
essentially identical results. 
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Figure 2. Effect of FcyR-blocking on proliferation induced by 
soluble anti-CD3 mAb or Con A. C57BWKa spleen cells were 
cultured in medium alone or medium supplemented with 2.462 
mAb, F(ab')z fragments of 2.462 or mIgG2a. Tcell mitogenesis 
was induced by addition of 10 pg/ml rat IgG2b, rat IgG2a or 
hamster anti-CD3 mAb. Data represent mean cpm of triplicate 
cultures ? SD. N.D. = not determined. Similar results were 
obtained in a second experiment (not shown). 
less mitogenic than the other mAb, whereas at lower con- 
centrations this mAb was significantly more mitogenic. 
The capacity of soluble anti-CD3 mAb to induce T cell pro- 
liferation has been shown to correlate with the extent of 
their interaction with FcyR [24]. Soluble rat IgG2b and rat 
IgG2a anti-CD3 mAb induced comparable T cell prolif- 
erations (Fig. 1 B). To induce T cell proliferation, high con- 
centrations (consistently 50-100 times higher than 145- 
2Cll mAb) of rat anti-CD3 mAb were needed. Neither of 
the isotype control mAb (PH2-4a, PH2-104 and GL3) 
induced proliferation (data not shown). 
Addition of FcyR-blocking mAb (10 pg/ml 2.462) com- 
pletely inhibited proliferation induced by all three soluble 
anti-CD3 mAb (Fig. 2). This inhibition was specific, since 
addition of 10 pg/ml of an isotype-control mAb (PH2-4a) 
had no effect on anti-CD3 mAb-induced proliferation 
(data not shown), and Con A induced proliferation was 
not affected by 2.462 mAb (Fig. 2). Highly purified 
F(ab'), fragments of 2.462 that only block FcyRIIIIII 
binding had a similar inhibitory effect to that of intact 
2.462 (Fig. 2). In addition, competition for FcyRI binding 
by adding 10 pg/ml P1.17 (mouse IgG2a) did not inhibit 
anti-CD3 mAb-induced T cell proliferation (Fig. 2). Thus, 
mitogenesis caused by all three anti-CD3 mAb involved 
FcyRIUIII molecules. The ability of low doses of hamster 
mAb to induce significant T cell proliferation suggests that 
this mAb has a high affinity for either FcyRII or FcyRIII. 
3.2 Effect of FcyR-blocking mAb on TNF-a release 
triggered by 145-2C11 in vivo 
Of the three anti-CD3 mAb, only 145-2C11 mAb induced 
cytokine-related side effects [6]. TNF-a has been shown to 
play a crucial role in these side effects [6, 91. Administra- 
tion of 10 pg hamster anti-CD3 mAb 145-2C11 in vivo 
induced a strong increase in serum TNF-a levels (Fig. 3). 
The highest TNF-a serum levels were measured 1 h after 
145-2C11 injection. To determine the role of FcyR in this 
TNF-a release, we temporarily blocked FcyR by giving 
250 pg 2.462 mAb 12 to 18 h before 145-2C11 injection. 
50 
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Figure 3. Effect of anti-FcyR mAb in vivo on TNF-a release trig- 
gered by 145-2C11 mAb. C57BL/Ka mice received either 10 pg 
145-2C11 mAb i.v. (t = 0 h), 250 pg 2.402 mAb (t = - 12 to - 18 h) 
or a combination of 145-2C11 and 2.4G2 mAb. Control mice 
received 0.5 ml BSS. At 1, 2, 4, 8 and 24 h after treatment, 3 
(2.462 and BSS group) or 5 (other groups) mice per group were 
killed for detection of serum TNF-a. This experiment was per- 
formed twice. Results represent the mean serum TNF-a levels 
(SEM 5 15 %) from one representative experiment. 
Treatment with 2.462 mAb completely abrogated the rise 
of serum TNF-a levels. Anti-FcyR mAb itself did not trig- 
ger TNF-a release. These results show that binding of 145- 
2Cll mAb to FcyR bearing cells is necessary for TNF-a 
release in vivo. 
3.3 Effect of FcyR blocking in vivo on 145-2Cll-induced 
immunosuppression of skin allograft rejection 
Since FcyR blockade significantly inhibited the cytokine 
release syndrome caused by 145-2C11 mAb, it was essen- 
tial to determine whether this treatment interferes with the 
immunosuppressive effect of this anti-CD3 mAb. There- 
fore, we studied the effect of the different treatment 
schedules on skin allograft rejection. The day after 145- 
2Cll  injection, C57BL/Ka mice received an MHC class II- 
disparate B6.C-H-2bm'2 skin graft. As shown in Fig. 4, a 
single dose of 10 pg 145-2C11 significantly prolonged skin 
allograft survival compared to the untreated control 
group. The administration of 250 pg 2.462 mAb had no 
Figure 4. Effect of FcyR-blockade in vivo on 145-2C11-induced 
immunosuppression of skin allograft rejection. C57BLKa mice 
received an MHC class 11-disparate B6.C-H-2bm'Z skin graft. On 
the day before grafting, the mice were treated with 10 pg 145-2C11 
(n = 8). One group received 250 pg 2.4G2 12 to 18 h before 145- 
2Cll administration (n = 7) and another received 2.4G2 mAb 
alone (n = 8). Control mice (n = 8) received no treatment. 
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immunosuppression. Though F(ab’), fragments have been 
proposed to be useful in the clinical situation, a major 
drawback of these fragments is their extremely short half- 
life and thus the necessity of frequent administration. In 
addition, the production of these fragments requires great 
care, since even minimal contamination with intact mAb 
may induce significant Tcell activation [26]. The use of 
whole non-mitogenic anti-CD3 mAb would therefore be 
much more preferable. An IgA switch variant of a murine 
anti-CD3 mAb, unable to interact with human FcyR, in- 
duces significantly less cytokine release and side effects in 
chimpanzees [28]. To date, the number of patients treated 
with these mAb are insufficient to allow conclusions on 
their immunosuppressive efficacy [29]. Alegre et al. [30] 
showed that mutations in the Fc portion of a humanized 
OKT3 resulted in reduced FcyR binding. In vitro, this 
mutated mAb also induced significantly less T cell activa- 
tion than the parental mAb, but displayed the same immu- 
nosuppressive properties. Recently, this mutated mAb has 
been shown to be equally effective in suppressing human 
skin graft rejection as the parental anti-CD3 mAb and 
OKT3 in SCID mice reconstituted with human splenocytes 
[311. 
effect on the immunosuppression induced by 145-2C11. 
Furthermore, the group that received 2.462 mAb alone 
showed the same graft survival as the untreated control 
group. These results show that FcyR-mediated binding of 
anti-CD3 mAb is not essential for immunosuppression. 
4 Discussion 
Treatment and prevention of organ allograft rejection 
using OKT3 is very successful [1, 21. However, this treat- 
ment is complicated by the OKT3-induced cytokine 
release syndrome. In this study, we used a mouse model 
with three anti-CD3 mAb to characterize the properties of 
anti-CD3 mAb that are responsible for induction of 
cytokine-related side effects. Since all three mAb have 
been shown to be equally immunosuppressive [6], this 
model allows the study of Tcell activating capacities of 
anti-CD3 mAb independent of their immunosuppressive 
properties. 
Differences in T cell activation by anti-CD3 mAb might be 
caused by differences in epitope recognition or affinity of 
the mAb [24, 251. Earlier studies [lo, 111 showed cross- 
competition between 17A2, KT3 and 145-2C11 mAb, sug- 
gesting that the three anti-CD3 mAb recognize similar or 
closely related epitopes. The hamster mAb 145-2C11 has 
been shown to be specific for the CD3 epsilon chain [7]. 
Furthermore, the anti-CD3 mAb bound with similar affin- 
ity (Kd of 2.5 X 10-9-3 X M) to lymph node cells (data 
not shown). 
Mitogenesis and Tcell activation in vitro caused by anti- 
CD3 mAb is dependent on interaction of these mAb with 
FcyR [26]. The finding that 145-2C11 F(ab‘), fragments 
induce less cytokine release and morbidity in mice than 
intact 145-2C11 mAb suggests that FcyR binding is also 
involved in Tcell activation in vivo [9, 271, though inter- 
pretations may be influenced by the short half-life of 
F(ab’), fragments. Our results demonstrate in a mouse 
model that intact non-mitogenic anti-CD3 mAb induced 
less cytokine-related side effects than mitogenic mAb [6]. 
This difference in mitogenesis is due to differences in FcR 
binding capacities of the antLCD3 mAb, since in immobi- 
lized form, all three mAb induced T cell proliferation. The 
mitogenic anti-CD3 mAb 145-2C11 displayed a higher 
affinity for FcyRII or FcyRIII than the non-mitogenic 
mAb 17A2 and KT3. The first direct evidence for the role 
of FcyR binding in the cytokine-related side effects of anti- 
CD3 mAb is provided by our finding that blocking of FcyR 
binding in vivo resulted in complete inhibition of TNF-a 
release by 145-2C11 mAb. 
Our previous study showed that the non-mitogenic rat 
anti-CD3 mAb 17A2 and KT3 are equally effective as the 
mitogenic 145-2C11 mAb in suppressing skin allograft 
rejection [6]. That FcyR binding of anti-CD3 mAb is not 
essential for their immunosuppressive properties is further 
shown by our finding that blocking of FcyR binding in vivo 
has no effect on the suppression of skin allograft rejection 
by 145-2C11 mAb. 
Together, our data suggest that the use of non-mitogenic 
anti-CD3 mAb would cause the induction of fewer 
cytokine-related side effects, while retaining effective 
In summary, interaction of the hamster antLCD3 mAb 
145-2C11 with FcyRIIIIII is responsible for its cytokine- 
related side effects. From a comparison of this mAb with 
two other anti-CD3 mAb that do not induce any morbid- 
ity, we conclude that mitogenesis in vitro correlates with 
cytokine release and morbidity in vivo. This finding is rele- 
vant for the development of new anti-CD3 mAb. Further- 
more, FcyR binding is not essential for immunosuppres- 
sion by anti-CD3 mAb. Together these data suggest that 
non-mitogenic anti-CD3 mAb are promising immunosup- 
pressive agents in clinical tissue and organ transplantation 
and that they may also be useful for treatment of autoim- 
mune diseases. 
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